This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): melagatran/ximelagatran
Description: Exanta (ximelagatran) is an oral direct thrombin inhibitor. The mechanism of action of Exanta is to inhibit the activity of a clot-forming enzyme called thrombin, which is critical to the final step in the formation of blood clots.
Additional information available to subscribers only: